2025 ASCO Archives - SOHO Insider

Skip to content

SOHO Egypt 2025 debuts with 2-day meeting in Cairo
FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML
FDA grants 510(k) clearance to multiple myeloma diagnostic platform
IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma
SOHO Young Investigator spotlight: Meet Maha Hameed, MD

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Dr. Du on unequal access to therapies in blood cancers

Cellular Therapy

Dr. Du on unequal access to therapies in blood cancers

Leukemia

Dr. Du on unequal access to therapies in blood cancers

Lymphoma

Dr. Du on unequal access to therapies in blood cancers

Multiple Myeloma

Dr. Du on unequal access to therapies in blood cancers

Myelodysplastic Syndromes

Dr. Du on unequal access to therapies in blood cancers

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

November 16, 2025

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Meetings / Conferences 2025 ASCO

2025 ASCO

News and highlights from the 2025 ASCO meeting in Chicago.

upclose shot of woman wearing glasses and a white coat

2025 ASCO News Video Interviews

Dr. Du on unequal access to therapies in blood cancers

by SOHO Insider Editors
September 12, 2025
0 Comments

SOHO Insider

2025 ASCO News

Dr. Kuykendall discusses VERIFY trial, rusfertide’s impact on PV treatment

by Leah Sherwood
July 1, 2025
0 Comments

GGM ASCO/EHA

2025 ASCO Video Interviews

Latest COMMANDS analysis shows luspatercept is transformative in MDS

by Leah Sherwood
June 24, 2025
0 Comments

SOHO Insider

2025 ASCO Video Interviews

What do the real-world data show on luspatercept in LR-MDS?

by SOHO Insider Editors
June 23, 2025
0 Comments

Multiple Myeloma. Multiple Myeloma disease blood test inmedical laboratory

2025 ASCO

Isatuximab with KRd boosts sustained MRD negativity in myeloma

by SOHO Insider Editors
June 5, 2025
0 Comments

Dna,Gene,Helix,Spiral,Molecule,Structure

2025 ASCO Meetings / Conferences

Phase 3 VERIFY study shows rusfertide significantly improves PV outcomes over SOC

by Leah Sherwood
June 4, 2025
0 Comments

Young scientists conducting research investigations in a medical laboratory, a researcher in the foreground is using a microscope

2025 ASCO

Sintilimab plus ICE regimen significantly improves complete remission in classical Hodgkin lymphoma

by SOHO Insider Editors
June 3, 2025
0 Comments

clipboard

2025 ASCO

Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML

by SOHO Insider Editors
June 1, 2025
0 Comments

Time to phase 3 symbol. Concept word Phase 1 2 3 on wooden block. Businessman hand. Beautiful grey table grey background. Business planning and time to phase 3 concept. Copy space.

2025 ASCO Meetings / Conferences

Phase 3 MIDAS trial assesses MRD-driven approach to consolidation, maintenance therapy in myeloma

by SOHO Insider Editors
May 31, 2025
0 Comments

pallatiative care

2025 ASCO Meetings / Conferences

Early palliative care integration does not reduce MM patients’ healthcare utilization

by Leah Sherwood
May 28, 2025
0 Comments

Top Categories

Cellular Therapy

13

Leukemia

66

Lymphoma

58

Multiple Myeloma

54

Myelodysplastic Syndromes

23

Myeloproliferative Neoplasms

12

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Early palliative care integration does not reduce MM patients’ healthcare utilization

Cellular Therapy

Early palliative care integration does not reduce MM patients’ healthcare utilization

Leukemia

Early palliative care integration does not reduce MM patients’ healthcare utilization

Lymphoma

Early palliative care integration does not reduce MM patients’ healthcare utilization

Multiple Myeloma

Early palliative care integration does not reduce MM patients’ healthcare utilization

Myelodysplastic Syndromes

Early palliative care integration does not reduce MM patients’ healthcare utilization

Myeloproliferative Neoplasms

Subscribe

Recent Posts

SOHO Egypt attendees

SOHO Egypt 2025 debuts with 2-day meeting in Cairo

FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML

FDA Green light

FDA grants 510(k) clearance to multiple myeloma diagnostic platform

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.